Then, they migrate to the draining lymph node and simultaneously cross‐present the antigens for priming of naive CD8+ T cells.[14, 15] The cross‐presentation is tightly regulated and disabled with tumor progression.[16] In contrast, mRNA vaccines, which can simulate natural MHC I type presentation, have natural superiority when applicated in cancer therapy. This evidence concerns the gene CD8A and cancer.